This is a preview of subscription content, log in via an institution to check access.
Notes
High-dose cyproterone is also used off-label as hormone therapy in gender reassignment, and in female patients for androgen-sensitive conditions (e.g. acne, hirsutism and baldness).
see Reactions 1274 p3; 801108658
A 36g cumulative exposure equated to a daily dose of cyproterone 100mg for 1 year.
Reference
Medicines and Healthcare products Regulatory Agency (UK). Cyproterone acetate: new advice to minimise risk of meningioma. Drug Safety Update 13: 2-4, No. 11, Jun 2020. Available from: URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/896274/June-2020-DSU-PDF.pdf
Rights and permissions
About this article
Cite this article
Cyproterone: dose-dependent increase in meningioma risk. Reactions Weekly 1812, 1 (2020). https://doi.org/10.1007/s40278-020-80480-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-80480-5